• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aprea Therapeutics, Inc. - Common Stock (NQ:APRE)

    0.9324 +0.0324 (+3.60%)
    Streaming Delayed Price Updated: 12:53 PM EST, Jan 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 106,168
    Open 0.9485
    Bid (Size) 0.9324 (7,400)
    Ask (Size) 0.9325 (100)
    Prev. Close 0.9000
    Today's Range 0.8737 - 0.9501
    52wk Range 0.8400 - 4.650
    Shares Outstanding 5,979,292
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
    From Aprea Therapeutics
    Via GlobeNewswire
    News headline image
    Game-Changing News: BEAT, APRE, TOON, MNTS, PRSO, PNPNF, SIGL – Stocks Under $1 Look Now
    Via AB Newswire

    Performance

    YTD
    +9.3%
    +9.3%
    1 Month
    -10.3%
    -10.3%
    3 Month
    -34.9%
    -34.9%
    6 Month
    -50.4%
    -50.4%
    1 Year
    -77.5%
    -77.5%

    More News

    Read More
    News headline image
    Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
    From Aprea Therapeutics
    Via GlobeNewswire
    News headline image
    Datavault AI (NASDAQ: DVLT) a Promising FY26 Forward Multiple, Reports +148% Q3, Expands Tokenization Globally – More Similar Stocks Inside.
    Via AB Newswire
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Aprea Therapeutics (Nasdaq: APRE) Advances Cancer Pipeline as Maxim Group Sets $10 Price Target
    Via AB Newswire
    News headline image
    Signal Advance (OTC: SIGL) CEO on The Street Podcast – Unveiling Physics-Based Encryption Built for the AI and Quantum Computing Era
    Via AB Newswire
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update
    From Aprea Therapeutics
    Via GlobeNewswire
    News headline image
    Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks Inside
    Via AB Newswire
    Topics Artificial Intelligence
    News headline image
    Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051
    From Aprea Therapeutics
    Via GlobeNewswire
    News headline image
    Mag 7 Undercard Stocks: PRSO, MIRA, WHWK, RDZN Surge on AI, Biotech, and Technology News – Full List Inside
    Via AB Newswire
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
    From Aprea Therapeutics
    Via GlobeNewswire
    News headline image
    Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
    From Aprea Therapeutics
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference
    From Aprea Therapeutics
    Via GlobeNewswire
    News headline image
    Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update
    From Aprea Therapeutics
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
    Via Benzinga
    News headline image
    Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
    From Aprea Therapeutics
    Via GlobeNewswire
    News headline image
    Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
    From Aprea Therapeutics
    Via GlobeNewswire
    News headline image
    Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
    From Aprea Therapeutics
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
    From Aprea Therapeutics
    Via GlobeNewswire
    News headline image
    Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
    From Aprea Therapeutics
    Via GlobeNewswire
    News headline image
    Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
    From Aprea Therapeutics
    Via GlobeNewswire
    News headline image
    Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
    From Aprea Therapeutics
    Via GlobeNewswire
    News headline image
    Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
    From Aprea Therapeutics
    Via GlobeNewswire

    Frequently Asked Questions

    Is Aprea Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Aprea Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Aprea Therapeutics, Inc. - Common Stock trade on?
    Aprea Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Aprea Therapeutics, Inc. - Common Stock?
    The ticker symbol for Aprea Therapeutics, Inc. - Common Stock is APRE on the Nasdaq Stock Market
    What is the current price of Aprea Therapeutics, Inc. - Common Stock?
    The current price of Aprea Therapeutics, Inc. - Common Stock is 0.9324
    When was Aprea Therapeutics, Inc. - Common Stock last traded?
    The last trade of Aprea Therapeutics, Inc. - Common Stock was at 01/08/26 12:53 PM ET
    What is the market capitalization of Aprea Therapeutics, Inc. - Common Stock?
    The market capitalization of Aprea Therapeutics, Inc. - Common Stock is 5.58M
    How many shares of Aprea Therapeutics, Inc. - Common Stock are outstanding?
    Aprea Therapeutics, Inc. - Common Stock has 6M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.